Lipidni status transrodnih osoba koje su na hormonskoj terapiji šest meseci
Sažetak
Uvod: Termin ‘’transrodan’’ odnosi se na osobe čiji se rodni identitet i/ili seksualno izražavanje razlikuje od pola pripisanog na rođenju. Transseksualizam se može dijagnostikovati u svim uzrastima, a prvi znaci se ispoljavaju još u najranijem detinjstvu. Ovakvo stanje se danas leči primenom hormonske i hirurške terapije u cilju usaglašavanja sa polom kome osoba psihički pripada.
Cilj rada: Utvrditi efekat terapije testosteronom na antropomorfne i metaboličke karakteristike, u transrodnih muškaraca.
Materijal i metode: Studijom je obuhvaćen 31 transmuškarac sa dijagnostikovanim poremećajem rodnog identiteta. Terapija testosteronom započeta je u proseku sa 26,03 ± 5,21 godina starosti. Pacijenti su lečeni na Klinici za endokrinologiju, dijabetes i bolesti metabolizma Kliničkog centra Srbije. Određivan je lipidni i hormonski status pre i tokom terapije.
Rezultati: Indeks telesne mase se značajno povećao. Nađen je značajan porast HDLa i Lp(a), a pad ApoA1. Do značajnih promena ostalih lipidnih parametara nije došlo. Tokom šest meseci terapije testosteronom FSH, LH i estradiol su značajno smanjeni. Koncentracija testosterona je signifikantno porasla. Nađen je porast broja eritrocita i hemoglobina.
Zaključak: Uz pravilnu primenu i doziranje, hormonska terapije ne dovodi do patološke alteracije lipidnog statusa.
Reference
- American Psychiatric Associtation. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC, USA: American Psychiatric Association Press; 2013.
- Vujović S, Slijepčević D, Rakić Z, Marić J, Perović S. Polni identitet i promena pola. Beograd: BIGZ; 1993.
- Walter Meyer III, Walter O. Bockting, Peggy Cohen-Kettenis, Eli Coleman, Domenico Diceglie, Louis Gooren et all. The Harry Benjamin International Gender Dysphoria Association's Standards of Care for Gender Identity Disorders, Sixth Version. Journal of Psychology & Human Sexuality. 2002; 13:1, 1-30
- International Statistical Classification of Diseases and Related Health Problems (11th ed,; ICD-11; World Health Organization, 2020).
- Gooren LJ, Giltay EJ. Review of studies of androgen treatment
of female-to-male transsexuals: Effects and risks of administration of androgens to females. J Sex Med. 2008;5:765–76.
- Vujovic, S., Popovic, S., Sbutega-Milosevic, G., Djordjevic, M., & Gooren, L. Transsexualism in Serbia: A Twenty-Year Follow-Up Study. J Sex Med. 2009; 6(4), 1018–1023.
- Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol. 2009;161:795- 798
- Pelusi C, Costantino A, Martelli V, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11:3002-3011
- Fernandez, J. D., & Tannock, L. R. Metabolic effects of hormone therapy in transgender patients. Endocrine Practice. 2016; 22(4), 383–388.
- Elamin, M. B., Garcia, M. Z., Murad, M. H., Erwin, P. J., & Montori, V. M. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clinical Endocrinology.2010; 72(1), 1–10.
- Ott, J., Aust, S., Promberger, R., Huber, J. C., & Kaufmann, U. Cross‐Sex Hormone Therapy Alters the Serum Lipid Profile: A Retrospective Cohort Study in 169 Transsexuals. The Journal of Sexual Medicine. 2011; 8(8), 2361–2369.
- Van Kesteren, P. J. M., Asscheman, H., Megens, J. A. J., & Gooren, L. J. G. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology. 1997; 47(3), 337–343.
- Bazarra-Castro MA, Sievers C, Fulda S, Klotsche J, Pieper L, et al. Comorbidities in Transsexual Patients under Hormonal Treatment Compared to Age- And Gender-Matched Primary Care Comparison Groups. Reproductive Sys Sexual Disord. 2012;